Hold the Cream and Sugar: Black Coffee Linked to Lower Risk of Death | Tufts Now
The American Food and Drug Administration (FDA) has approved a long -term drug lock, developed by Gillid Sciences, as a preventive HIV treatment. Marketed as Sunlanka, this is the first HIV-PRE exposure profile practice (prep) that requires administration only every six months, and provides success to individuals struggling with daily pills or more frequent doses. Linkapavir works by preventing the HIV virus from entering healthy cells, and the approval of it follows successful clinical studies showing strong efficiency to prevent HIV transfer. The purpose of the drug is to benefit from especially HIV -affected groups, including black and Latino communities, transgendered women and others, who can withstand challenges with existing PREP options. Experts believe that this bipolar alternative can expand access and follow for HIV prevention. Gilliad is now planning to provide Linkapavir to Linkapavir in 2024, while global health organizations also emphasize wide, cheap distribution in countries with low incomes.
Read full Story »Disclaimer: This preview includes title, image, and description automatically sourced from the original website (now.tufts.edu) using publicly available metadata / OG tags. All rights, including copyright and content ownership, remain with the original publisher. If you are the content owner and wish to request removal, please contact us from your official email to no_reply@newspaperhunt.com.
